A Pilot Study of Unrelated Cord Blood (UCB) Transplantation and Unmatched Human Placental Derived Stem Cells (HPDSC) in Pediatric Malignant and Non-Malignant Disease

kg child this yields 4x103 and 104 cells/kg, respectively, of pathogen-specific T cells, which is consistent with the numbers needed to treat chemotherapy-refractory CMV in clinical trials using the first generation technology. We are implementing a pre-screening approach to identify CMV seropositive donors that may fail to collect and extending our evaluation of the Prodigy system to capture pathogen-specific T cells with specificity other than CMV. These data demonstrate automated production of CMV-specific T cells is feasible and will enable investigators to produce clinicalgrade pathogen specific allogeneic T cells for add-back after HSCT at multiple points-of-care broadening the application of this promising immunotherapy.